At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 4 enrolled
Drug / intervention
LL37 +1 morebiological
Likely dose
LL37 250 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Induction of Antitumor Response in Melanoma Patients Using the Antimicrobial Peptide LL37
In Brief
A Phase 2 clinical trial evaluating LL37 and Photographs for Melanoma. Completed, enrolled 4 participants across 1 site.
Detailed Summary
The goal of this clinical research study is to find the appropriate dose of LL37 that can be given to patients with melanoma. Researchers also want to learn if LL37 can stimulate the immune system to help control the disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 2014
Enrollment StartJul 2015
Primary CompletionNov 2020
TodayJul 2026
First PostedAug 26, 2014
Enrollment StartJul 8, 2015
Primary CompletionNov 24, 2020
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 11.8 years ago
Interventions
LL37biological
Starting dose 250 µg/tumor. The injections will be given every 7 days for up to 8 weeks.
Photographsother
Tumors measured and photographed one week before receiving LL37, and again at 4 weeks after LL37. Then photographs of the LL37 injected sites taken at 8 weeks.